BACKGROUND: The number of female smokers developing chronic obstructive pulmonary disease (COPD) is rapidly increasing, but whether or not there exists a differential susceptibility by gender remains controversial. METHODS: How smoking behaviour and subsequent lung function reduction differed by gender was examined in a study including 954 subjects with COPD and 955 subjects without COPD. The study focused on two subgroups: subjects with COPD <60 years of age (early-onset group, n=316) and subjects with COPD with <20 pack-years of smoking (low exposure group, n=241). RESULTS: In the low exposure group, female subjects with COPD had lower forced expiratory volume in 1 s (FEV(1)) % predicted (48.7% vs 55.8%, p=0.001) and more severe disease (50.4% vs 35.6%, p=0.020, in GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 3 and 4) than male subjects with COPD. Females also had lower FEV(1)% predicted (50.6% vs 56.0%, p=0.006) and more severe COPD (41.7% vs 31.1% in GOLD stage 3 and 4, p=0.050) in the early-onset group. Using multivariate regression, female gender was associated with 5.7% lower FEV(1)% predicted in the low exposure group (p=0.012) and a similar trend was observed in the early-onset group (p=0.057). The number of pack-years was not significantly associated with lung function in female subjects with COPD in this study, and the dose-response relationship between smoking and lung function differed by gender at lower levels of smoking exposure. Interaction analysis suggested that the effect of smoking on lung function might be different by gender (p=0.027 in all subjects with COPD). CONCLUSIONS: Female gender was associated with lung function reduction and more severe disease in subjects with COPD with early onset of disease or low smoking exposure. The findings may suggest a gender difference in susceptibility to the lung-damaging effects of cigarette smoking, but alternative explanations should be considered.
BACKGROUND: The number of female smokers developing chronic obstructive pulmonary disease (COPD) is rapidly increasing, but whether or not there exists a differential susceptibility by gender remains controversial. METHODS: How smoking behaviour and subsequent lung function reduction differed by gender was examined in a study including 954 subjects with COPD and 955 subjects without COPD. The study focused on two subgroups: subjects with COPD <60 years of age (early-onset group, n=316) and subjects with COPD with <20 pack-years of smoking (low exposure group, n=241). RESULTS: In the low exposure group, female subjects with COPD had lower forced expiratory volume in 1 s (FEV(1)) % predicted (48.7% vs 55.8%, p=0.001) and more severe disease (50.4% vs 35.6%, p=0.020, in GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 3 and 4) than male subjects with COPD. Females also had lower FEV(1)% predicted (50.6% vs 56.0%, p=0.006) and more severe COPD (41.7% vs 31.1% in GOLD stage 3 and 4, p=0.050) in the early-onset group. Using multivariate regression, female gender was associated with 5.7% lower FEV(1)% predicted in the low exposure group (p=0.012) and a similar trend was observed in the early-onset group (p=0.057). The number of pack-years was not significantly associated with lung function in female subjects with COPD in this study, and the dose-response relationship between smoking and lung function differed by gender at lower levels of smoking exposure. Interaction analysis suggested that the effect of smoking on lung function might be different by gender (p=0.027 in all subjects with COPD). CONCLUSIONS: Female gender was associated with lung function reduction and more severe disease in subjects with COPD with early onset of disease or low smoking exposure. The findings may suggest a gender difference in susceptibility to the lung-damaging effects of cigarette smoking, but alternative explanations should be considered.
Authors: Meilan K Han; Dirkje Postma; David M Mannino; Nicholas D Giardino; Sonia Buist; Jeffrey L Curtis; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2007-08-02 Impact factor: 21.405
Authors: E K Silverman; S T Weiss; J M Drazen; H A Chapman; V Carey; E J Campbell; P Denish; R A Silverman; J C Celedon; J J Reilly; L C Ginns; F E Speizer Journal: Am J Respir Crit Care Med Date: 2000-12 Impact factor: 21.405
Authors: Emily S Wan; Weiliang Qiu; Vincent J Carey; Jarrett Morrow; Helene Bacherman; Marilyn G Foreman; John E Hokanson; Russell P Bowler; James D Crapo; Dawn L DeMeo Journal: Am J Respir Cell Mol Biol Date: 2015-08 Impact factor: 6.914
Authors: Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make Journal: Chest Date: 2019-05-30 Impact factor: 9.410
Authors: Dinesh Devadoss; Christopher Long; Raymond J Langley; Marko Manevski; Madhavan Nair; Michael A Campos; Glen Borchert; Irfan Rahman; Hitendra S Chand Journal: Am J Respir Cell Mol Biol Date: 2019-12 Impact factor: 6.914
Authors: Ruby C Lo; Rodney P Bensley; Allen D Hamdan; Mark Wyers; Julie E Adams; Marc L Schermerhorn Journal: J Vasc Surg Date: 2013-02-04 Impact factor: 4.268